Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients?
Background: Acyclovir is a hydrophilic drug that is mainly distributed in the lean compartments of the body. Consequently, dosing on total body weight in obese patients may lead to drug overdosing. Inconsistency in clinical guideline recommendations and a lack of clear recommendations in the Summary...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-10-01
|
| Series: | Clinical Infection in Practice |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590170220300339 |
| _version_ | 1818601041155850240 |
|---|---|
| author | Bastiaan TGM Sallevelt Erin H Smeijsters Toine CG Egberts Kim CM van der Elst Tania Mudrikova |
| author_facet | Bastiaan TGM Sallevelt Erin H Smeijsters Toine CG Egberts Kim CM van der Elst Tania Mudrikova |
| author_sort | Bastiaan TGM Sallevelt |
| collection | DOAJ |
| description | Background: Acyclovir is a hydrophilic drug that is mainly distributed in the lean compartments of the body. Consequently, dosing on total body weight in obese patients may lead to drug overdosing. Inconsistency in clinical guideline recommendations and a lack of clear recommendations in the Summary of Product Characteristics on how to dose acyclovir in obese patients can impede safe and effective treatment. Case report: This report describes a 71-year-old obese patient (body mass index 35 kg/m2) with herpes zoster ophthalmicus and meningoencephalitis. The patient had normal renal function and was treated with acyclovir with a dosage based on actual body weight (10 mg/kg q8h intravenously). Supratherapeutic acyclovir concentrations probably induced acute kidney injury (AKI) and neurotoxicity. Results: Due to the severity of the toxic effects, multiple sessions of hemodialysis were necessary, with eventual full recovery of the renal function and neurotoxic symptoms. Low dose haloperidol and lorazepam were not effective in resolving audiovisual hallucinations in our patient. Conclusion: This case report emphasizes the need for adjusted dosing and subsequent close monitoring of obese patients who are treated with hydrophilic drugs, such as acyclovir, to avoid patient harm. We discuss prevention and management strategies for acyclovir toxicity in obese patients based on the current literature. |
| first_indexed | 2024-12-16T12:45:04Z |
| format | Article |
| id | doaj.art-13c879c06bfd453090979d0c9b3fd4aa |
| institution | Directory Open Access Journal |
| issn | 2590-1702 |
| language | English |
| last_indexed | 2024-12-16T12:45:04Z |
| publishDate | 2020-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Infection in Practice |
| spelling | doaj.art-13c879c06bfd453090979d0c9b3fd4aa2022-12-21T22:31:18ZengElsevierClinical Infection in Practice2590-17022020-10-017100046Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients?Bastiaan TGM Sallevelt0Erin H Smeijsters1Toine CG Egberts2Kim CM van der Elst3Tania Mudrikova4Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands; Corresponding author at: University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the NetherlandsDepartment of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the NetherlandsDepartment of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the NetherlandsDepartment of Internal Medicine, University Medical Center Utrecht, Utrecht, the NetherlandsBackground: Acyclovir is a hydrophilic drug that is mainly distributed in the lean compartments of the body. Consequently, dosing on total body weight in obese patients may lead to drug overdosing. Inconsistency in clinical guideline recommendations and a lack of clear recommendations in the Summary of Product Characteristics on how to dose acyclovir in obese patients can impede safe and effective treatment. Case report: This report describes a 71-year-old obese patient (body mass index 35 kg/m2) with herpes zoster ophthalmicus and meningoencephalitis. The patient had normal renal function and was treated with acyclovir with a dosage based on actual body weight (10 mg/kg q8h intravenously). Supratherapeutic acyclovir concentrations probably induced acute kidney injury (AKI) and neurotoxicity. Results: Due to the severity of the toxic effects, multiple sessions of hemodialysis were necessary, with eventual full recovery of the renal function and neurotoxic symptoms. Low dose haloperidol and lorazepam were not effective in resolving audiovisual hallucinations in our patient. Conclusion: This case report emphasizes the need for adjusted dosing and subsequent close monitoring of obese patients who are treated with hydrophilic drugs, such as acyclovir, to avoid patient harm. We discuss prevention and management strategies for acyclovir toxicity in obese patients based on the current literature.http://www.sciencedirect.com/science/article/pii/S2590170220300339AcyclovirPharmacokineticsDrug-related side effects and adverse reactionsDrug monitoringObesity |
| spellingShingle | Bastiaan TGM Sallevelt Erin H Smeijsters Toine CG Egberts Kim CM van der Elst Tania Mudrikova Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients? Clinical Infection in Practice Acyclovir Pharmacokinetics Drug-related side effects and adverse reactions Drug monitoring Obesity |
| title | Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients? |
| title_full | Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients? |
| title_fullStr | Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients? |
| title_full_unstemmed | Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients? |
| title_short | Acute renal and neurotoxicity due to weight-based dosing of intravenous acyclovir: How to dose in obese patients? |
| title_sort | acute renal and neurotoxicity due to weight based dosing of intravenous acyclovir how to dose in obese patients |
| topic | Acyclovir Pharmacokinetics Drug-related side effects and adverse reactions Drug monitoring Obesity |
| url | http://www.sciencedirect.com/science/article/pii/S2590170220300339 |
| work_keys_str_mv | AT bastiaantgmsallevelt acuterenalandneurotoxicityduetoweightbaseddosingofintravenousacyclovirhowtodoseinobesepatients AT erinhsmeijsters acuterenalandneurotoxicityduetoweightbaseddosingofintravenousacyclovirhowtodoseinobesepatients AT toinecgegberts acuterenalandneurotoxicityduetoweightbaseddosingofintravenousacyclovirhowtodoseinobesepatients AT kimcmvanderelst acuterenalandneurotoxicityduetoweightbaseddosingofintravenousacyclovirhowtodoseinobesepatients AT taniamudrikova acuterenalandneurotoxicityduetoweightbaseddosingofintravenousacyclovirhowtodoseinobesepatients |